Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but
almost always develop resistance within several months of initiating therapy 1 , 2 . The …

Which genetic alterations drive tumorigenesis and how they evolve over the course of
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …

10.7554/eLife.00747.001 In solid tumors, targeted treatments can lead to dramatic regressions,
but responses are often short-lived because resistant cancer cells arise. The major …

The spread of cancer cells from primary tumors to regional lymph nodes is often associated
with reduced survival. One prevailing model to explain this association posits that fatal, …

The extent of heterogeneity among driver gene mutations present in naturally occurring
metastases—that is, treatment-naive metastatic disease—is largely unknown. To address this …

Clonal hematopoiesis, a condition in which individual hematopoietic stem cell clones
generate a disproportionate fraction of blood leukocytes, correlates with higher risk for …

Metastases are responsible for the majority of cancer-related deaths. Although genomic
heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-…

Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication.
Any two randomly selected cells, whether normal or cancerous, are therefore genetically …

Early cancer detection aims to find tumors before they progress to an incurable stage. To
determine the potential of circulating tumor DNA (ctDNA) for cancer detection, we developed a …

Reconstructing the evolutionary history of metastases is critical for understanding their basic
biological principles and has profound clinical implications. Genome-wide sequencing data …